Dianthus Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Dianthus Therapeutics

10/05/2024 16:04

* Dianthus Therapeutics Inc  DNTH.OQ   DNTH.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 1
(estimated) for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $470.5 thousand, according to the mean estimate from
4 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Dianthus Therapeutics
Inc is
for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 39.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Dianthus
Therapeutics Inc is $47.00​, above​ its last closing price
of $24.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.44       -0.44      -0.54     Missed  -23.3
 Dec. 31 2024  -1.18       -1.01      -0.71     Beat    29.7
 Sep. 30 2023  -0.56       -0.56      -3.78     Missed  -575​
 Jun. 30 2023  -3.04       -3.04      -0.80     Beat    73.7
 ​​Mar.        -6.56       -6.56      -7.68     Missed  -17.1
 31 2023                                                
 Dec. 31 2022  -3.68       -4.32      -5.44     Missed  -25.9​
 Sep. 30 2022  -4.85       -4.80      -4.32     Beat    10
 Jun. 30 2022  -5.58       -5.28      -4.64     Beat    12.1
 This summary was machine generated May 10 at 15:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)